SOHO State of the Art Updates and Next Questions: Novel Therapies in T-ALL: From CAR-T to Novel Targets.
Two established drugs show strong early promise in hard-to-treat T-cell leukemias, with one achieving disease-free survival over 90% in young patients.
This SOHO-commissioned review synthesizes genomic advances and novel therapy trials in T-ALL, highlighting nelarabine's survival benefit in pediatric/AYA patients (92.2% 4-year DFS) and early-phase CAR-T and daratumumab data showing high response rates in relapsed/refractory disease. Key genomic subtypes and targeted small molecule inhibitors under investigation are also reviewed.
What the study was
- Study design
- Narrative review
- Population
- Pediatric, adolescent/young adult, and adult patients with T-cell ALL
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Clinical Lymphoma Myeloma and Leukemia
Why it surfaced
SOHO-invited review synthesizing T-ALL novel therapy landscape; useful context but no new primary data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.